BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2023
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil pares losses as market weighs Saudi supply concerns, Middle East tensions
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
BioXcel Therapeutics (BTAI) PT Lowered to $7 at BofA Securities
March 13, 2024 6:13 AM EDTBofA Securities analyst Geoff Meacham lowered the price target on BioXcel Therapeutics (NASDAQ: BTAI) to $7.00 (from $8.00) while maintaining a Buy rating.
The analyst comments "BioXcel announced a 4Q23 update as the company continues to finalize the clinical programs (see report) designed... More
